Professor Gerd Kullak-Ublick - 'Understanding drug safety: the academic and the industry perspective'
1:00pm - 2:00pm /
Thursday 18th June 2026
/ Online event
Type: Webinar /
Category: Research
- ISMIB Seminar Team
- Suitable for: All are welcome.
- Admission: Free to attend
- Online location
Add this event to my calendar
Click on "Create a calendar file" and your browser will download a .ics file for this event.
Microsoft Outlook: Download the file, double-click it to open it in Outlook, then click on "Save & Close" to save it to your calendar. If that doesn't work go into Outlook, click on the File tab, then on Open & Export, then Open Calendar. Select your .ics file then click on "Save & Close".
Google Calendar: download the file, then go into your calendar. On the left where it says "Other calendars" click on the arrow icon and then click on Import calendar. Click on Browse and select the .ics file, then click on Import.
Apple Calendar: The file may open automatically with an option to save it to your calendar. If not, download the file, then you can either drag it to Calendar or import the file by going to File >Import > Import and choosing the .ics file.
Gerd Kullak-Ublick is a medical doctor and obtained board certification in Internal Medicine, Gastroenterology, and Clinical Pharmacology and Toxicology at Munich University Hospital Grosshadern, Germany, and at the University Hospital Zurich, Switzerland, where he trained from 1991-2005. In 2001, Gerd obtained an Assistant Professorship funded by the Swiss National Science Foundation. From 2006-2025, Gerd was Full Professor of Clinical Pharmacology and Toxicology at the University of Zurich.
He also acted as the Global Head of Mechanistic Safety and as Chair of the Hepatic Safety team at Novartis, Basel, from 2009-2025. Gerd’s research interests are centered on the molecular and functional characterization of drug and bile acid transporters, drug-induced liver and kidney injury and the role of nuclear receptors in the regulation of transporters and as drug targets for the treatment of liver and metabolic disease. Gerd was work package leader of the work package “Drug-induced liver injury” in the IMI TransBioLine consortium (evaluation of novel biomarkers in drug-induced liver injury) and is a core member of the Pro-Euro DILI Network, Europe.
Gerd continues working on Drug-Induced Liver injury as Honorary Senior Fellow at the University of Liverpool and as Honorary Professor at the University of Malaga, Spain, both these universities having a strong track record in Drug-Induced Liver injury. Gerd was co-founder of TransHeps, a spin-off company of the University of Zurich which focusses on the development of an in vitro DILI causality assay called MetaHeps. Gerd also works closely with biotech companies interested in developing AI-based new approach methodologies (NAMs) for drug safety testing.
He also acted as the Global Head of Mechanistic Safety and as Chair of the Hepatic Safety team at Novartis, Basel, from 2009-2025. Gerd’s research interests are centered on the molecular and functional characterization of drug and bile acid transporters, drug-induced liver and kidney injury and the role of nuclear receptors in the regulation of transporters and as drug targets for the treatment of liver and metabolic disease. Gerd was work package leader of the work package “Drug-induced liver injury” in the IMI TransBioLine consortium (evaluation of novel biomarkers in drug-induced liver injury) and is a core member of the Pro-Euro DILI Network, Europe.
Gerd continues working on Drug-Induced Liver injury as Honorary Senior Fellow at the University of Liverpool and as Honorary Professor at the University of Malaga, Spain, both these universities having a strong track record in Drug-Induced Liver injury. Gerd was co-founder of TransHeps, a spin-off company of the University of Zurich which focusses on the development of an in vitro DILI causality assay called MetaHeps. Gerd also works closely with biotech companies interested in developing AI-based new approach methodologies (NAMs) for drug safety testing.